Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTXABCW)

• DTT Name: NT-3 growth factor receptor (TrkC) DTT Info
• Gene Name: NTRK3

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[1]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[2]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[3]
Altiratinib	DMUJCBT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

10 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3-amino-5-benzyl-substituted indazole derivative 1	DMFDURZ	Chronic pain	MG30	Patented	[5]
Azaindazole amide derivative 1	DMJWH4B	Chronic pain	MG30	Patented	[5]
Cyclopenta[d]pyrimidine derivative 1	DMKM6BY	N. A.	N. A.	Patented	[4]
PMID28270010-Compound-Figure24-b	DM0QHLK	N. A.	N. A.	Patented	[4]
PMID28270010-Compound-Figure5-1	DM2YAPJ	N. A.	N. A.	Patented	[4]
PMID28270010-Compound-Figure5-2	DMK3GRZ	N. A.	N. A.	Patented	[4]
PMID28270010-Compound-Figure5-3	DMSOT1R	N. A.	N. A.	Patented	[4]
PMID28270021-Compound-WO2015042088Example4	DM6KXOQ	Chronic pain	MG30	Patented	[5]
PMID28270021-Compound-WO2016054807Example1	DMD5QEL	Chronic pain	MG30	Patented	[5]
Pyrrolo[2,3-d]pyrimidine derivative 4	DME0WSR	Chronic pain	MG30	Patented	[5]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CEP-2563	DMH1PQ0	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[6]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD1332	DM0PVD9	Discovery agent	N.A.	Investigative	[7]
GNF-5837	DMYJO13	Discovery agent	N.A.	Investigative	[8]
JNJ-28312141	DMCMH7O	Discovery agent	N.A.	Investigative	[9]
PMID21493067C1d	DMFUQIT	Discovery agent	N.A.	Investigative	[10]
PMID24900538C2c	DM5PATM	Discovery agent	N.A.	Investigative	[11]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [3] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [4] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [5] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
• [6] Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1817).
• [8] Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5.
• [9] JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
• [10] In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61.
• [11] Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.